Soluble CD40 ligand is an early initiator of inflammation after coronary intervention

Coronary Artery Disease

Volumn 15, Issue 8, 2004, Pages 471-475

  Aggarwal, Atul ^a   Blum, Arnon ^b   Schneider, David J ^c   Sobel, Burton E ^c   Dauerman, Harold L ^c  

^a Nebraska Heart Institute   (United States)

^b Poriya Hospital   (Israel)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Inflammation; Stent

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; NITRATE; STATINE DERIVATIVE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKINS; MALE; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES;

EID: 15744372035     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200412000-00003     Document Type: Article

References (23)

1. Versaci F, Gaspardone A, Tomai F, Crea F, Chiarlello L, Gioffre PA. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 2000; 85: 92-95.
2. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104:992-997.
3. Gaspardone A, Crea F, Versaci F, Tomai F, Pellegrino A, Chiariello L, Gioffre PA. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol 1998; 82:515-518.
4. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000; 21:1152-1158.
5. Blum A, Sclarovsky S, Shohat B. T-Lymphocyte activation in stable angina pectoris and after percutaneous transluminal coronary angioplasty. Circulation 1 995; 91:20-22.
6. Patti G, Di Sciascio G, D'Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 2002; 89:372-376.
7. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
8. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003; 108:2776-2782.
9. Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol 2003; 92: 924-929.
10. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002; 40:1935-1942.
11. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003; 107:1123-1128.
12. Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 2004; 93:6-9.
13. Aggarwal A, Schneider DJ, Terrien EF, Terrien CM, Sobel BE, Dauerman HL. Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 2003; 91:1346-1349.
14. Braunwald E. Unstable angina: a classification. Circulation 1989; 80: 410-414.
15. Dickson WJ. BDMP Statistical Software, Vol 1. Berkeley, CA: University of California Press; 1992.
16. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104:163-167.
17. Welt FG, Rogers SD, Zhang X, Ehlers R, Chen Z, Nannizzi-Alaimo L, et al. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc Interv 2004; 61:185-189.
18. Bonz AW, Lengenfelder B, Jacobs M, Strotmann J, Held S, Ertl G, Voelker W. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J 2003; 145:693-699.
19. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98:2370-2376.
20. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106:896-899.
21. Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, et al. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. Heart 2003; 89:1200-1204.
22. Bauters C, Hubert E, Prat A, Bougrimi K, Van Belle E, McFadden EP, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998; 31:1291-1298.
23. Dalby M, Montalescot G, Sollier CB, Vicaut E, Soulat T, Collet JP, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 2004; 43: 162-168.